Latest Videos Archives

TMPRSS2, ACE 2, and the Potential Role of 5ARIs and GNRH Analogues in Inhibiting COVID-19 Infection

Posted by David Utz | May 2020

L. Michael Glodé, MD, FACP, Professor Emeritus at the University of Colorado Cancer Center and a medical oncologist at the Shaw Regional Cancer Center in Edwards, Colorado, discusses the mechanism of action of the TMPRSS2 and ACE2 pathways, and their relationship to the host-cell entry of COVID-19. He goes on to discuss a clinical trial using the serine protease inhibitor Camostat, noting how 5ARIs and GNRH analogues could act as a target for prevention and possible treatment of COVID-19. He also discusses the results of an Italian observational study which demonstrated how prostate cancer patients receiving ADT appear to be partially protected from COVID-19 infection.

Tele-Huddle: The Best Two Minutes You Can Spend With Your Staff

Posted by Neil H. Baum, MD | May 2020

Neil H. Baum, MD, Clinical Professor of Urology at Tulane Medical School in New Orleans, Louisiana, discusses how urologists and other physicians can manage negative online reviews. He emphasizes the importance of not getting defensive, and explains how to best control the fallout of a negative review. Dr. Baum advises physicians to check their online reviews at least once a month, and to remember that while negative reviews are most often not about clinical issues, they still reflect a vital aspect of the patient’s experience with the practice. He also advises that doctors should respond directly to the negative review both online and offline. Finally, he recommends increasing the number of positive reviews by asking happy patients to review their experience immediately, and also recommends staying away from ratings-boosting services.

Next Generation Biomarkers – As Reflex, Combination, or First Line?

Posted by E. David Crawford, MD | May 2020

E. David Crawford, MD, Editor-in-Chief of Grand Rounds in Urology and Professor of Urology at University of California, San Diego, gives his expertise on next generation biomarkers in prostate cancer screening. Firstly, Dr. Crawford qualifies the new standard of PSA >1.5 ng/mL, specifically how it aids in early detection of disease and acts as a surrogate for BPH, prostate cancer, and prostatitis. Following this, Dr. Crawford reviews the clinical needs and genomic markers of prostate cancer. In conclusion, he describes his algorithm for PSA screening.

Stress Urinary Incontinence: Non-Mesh Alternatives

Posted by Una Lee, MD, FPMRS | May 2020

Una Lee, MD, FPMRS, urologist and researcher at Virginia Mason Medical Center, reviews the evidence on non-mesh alternatives for stress urinary incontinence (SUI). She provides an overview of the causes of female SUI, presents an effective treatment tree addressing both overactive bladder and stress incontinence, and discusses treatment options. Dr. Lee encourages physicians to consider how they present treatment decisions in order to allow patients to make the choice that fits best for them. In addition to covering all possible risks and benefits, she advises physicians to also educate patients on their condition and help manage their expectations for treatment outcomes.

UPDATED: Next-Generation Sequencing of DNA in Prosthetic Urology: Promising Early Results

Posted by Gerard D. Henry, MD | May 2020

Gerard D. Henry, MD, a urologist with Ark-La-Tex Urology in Bossier City, Louisiana, discusses pathogen identification using next generation sequencing (NGS) in a urology-based setting. He goes on to describe the utility of PCR+NGS, discusses several case-studies demonstrating its superior performance compared to traditional culture, and presents the results of a single-center study demonstrating the benefit of using NGS vs traditional culture for pathogen identification in 101 patients after IPP.